Back to today’s briefing

Story perspectives

FDA Approves Uplizna: First Treatment for IgG4-RD

6/3/2025

39 4

Summary

Story summary

In a groundbreaking move, the FDA has greenlit Amgen's Uplizna as the first-ever treatment for Immunoglobulin G4-related disease (IgG4-RD), a rare autoimmune disorder. The MITIGATE trial revealed a staggering 87% reduction in disease flare-ups, offering hope to patients who previously had no approved options. Excitingly, further research is set to explore its potential for other immune-related conditions.

1 of 1

Story summary

In a groundbreaking move, the FDA has greenlit Amgen's Uplizna as the first-ever treatment for Immunoglobulin G4-related disease (IgG4-RD), a rare autoimmune disorder. The MITIGATE trial revealed a staggering 87% reduction in disease flare-ups, offering hope to patients who previously had no approved options. Excitingly, further research is set to explore its potential for other immune-related conditions.